REGN3918

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Healthy VolunteersParoxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

CompletedNCT03115996

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2017-05-10End: 2018-08-31Updated: 2018-09-26

Phase 2

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

CompletedNCT03946748

Regeneron PharmaceuticalsParoxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2019-05-16End: 2021-06-10Updated: 2023-06-26

Phase 3

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

TerminatedNCT04162470

Regeneron PharmaceuticalsParoxysmal Nocturnal Hemoglobinuria

Start: 2019-12-03End: 2022-04-07Updated: 2023-06-12

Related Papers

Psychometric Evaluation of the PNH Symptom Questionnaire (PNH-SQ) Among Patients with Paroxysmal Nocturnal Hemoglobinuria from Three Phase 2 Clinical Trials with Pozelimab Monotherapy or in Combination with Cemdisiran

Blood2023-11-02

P775: LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

HemaSphere2023-08-012 citations

Association of complement pathways with COVID-19 severity and outcomes.

2022-12-079 citations

Long-Term Efficacy and Safety of Pozelimab Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Blood2022-11-152 citations

A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Blood2022-11-151 citations

Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

Blood2021-11-058 citations

Interim Analysis of an Open-Label, Ascending-Dose, Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of the Subcutaneously Administered Human Monoclonal Antibody Pozelimab in Combination with Single Doses of the Subcutaneously Administered siRNA Cemdisiran in Healthy Volunteers

Blood2021-11-053 citations

A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria

Blood2019-11-131 citations